BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18791128)

  • 1. Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
    Tomoda C; Moatamed F; Naeim F; Hershman JM; Sugawara M
    Exp Biol Med (Maywood); 2008 Nov; 233(11):1433-40. PubMed ID: 18791128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
    Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
    Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase.
    Quidville V; Segond N; Pidoux E; Cohen R; Jullienne A; Lausson S
    Endocrinology; 2004 May; 145(5):2561-71. PubMed ID: 14736730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in medullary thyroid carcinoma.
    Zhang Q; Meng X; Zheng G; Chen G; Pang R; Hua T; Yang S
    Mol Med Rep; 2014 Feb; 9(2):768-72. PubMed ID: 24346019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells.
    Du ZX; Zhang HY; Gao DX; Wang HQ; Li YJ; Liu GL
    Exp Mol Med; 2006 Jun; 38(3):230-40. PubMed ID: 16819281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.
    Zatelli MC; Luchin A; Piccin D; Tagliati F; Bottoni A; Vignali C; Bondanelli M; degli Uberti EC
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5754-60. PubMed ID: 16091477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis.
    Erickson BA; Longo WE; Panesar N; Mazuski JE; Kaminski DL
    J Surg Res; 1999 Jan; 81(1):101-7. PubMed ID: 9889067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
    Quidville V; Segond N; Lausson S; Frenkian M; Cohen R; Jullienne A
    Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):14-30. PubMed ID: 16997128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines.
    Cheng J; Imanishi H; Amuro Y; Hada T
    Int J Cancer; 2002 Jun; 99(5):755-61. PubMed ID: 12115513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest.
    Detjen KM; Welzel M; Wiedenmann B; Rosewicz S
    Int J Cancer; 2003 Dec; 107(5):844-53. PubMed ID: 14566837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo.
    Eli Y; Przedecki F; Levin G; Kariv N; Raz A
    Biochem Pharmacol; 2001 Mar; 61(5):565-71. PubMed ID: 11239499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
    Kunnimalaiyaan M; Ndiaye M; Chen H
    Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro.
    Ferrari SM; Fallahi P; La Motta C; Bocci G; Corrado A; Materazzi G; Galleri D; Piaggi S; Danesi R; Da Settimo F; Miccoli P; Antonelli A
    Surgery; 2014 Nov; 156(5):1167-76. PubMed ID: 25151558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
    Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
    J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.